Happy Thanksgiving! Save 50% on Your MarketBeat All Access Subscription.
Special Offer: Just $199
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,963.94 (-1.54%)
DOW   33,849.46 (-1.45%)
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.17 (-1.53%)
S&P 500   3,963.94 (-1.54%)
DOW   33,849.46 (-1.45%)
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.17 (-1.53%)
S&P 500   3,963.94 (-1.54%)
DOW   33,849.46 (-1.45%)
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.17 (-1.53%)
S&P 500   3,963.94 (-1.54%)
DOW   33,849.46 (-1.45%)
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.17 (-1.53%)
NASDAQ:STOK

Stoke Therapeutics - STOK Stock Forecast, Price & News

$7.34
+0.01 (+0.14%)
(As of 11/28/2022 12:00 AM ET)
Add
Compare
Today's Range
$7.08
▼
$7.55
50-Day Range
$7.33
▼
$15.69
52-Week Range
$7.08
▼
$26.60
Volume
430,795 shs
Average Volume
301,831 shs
Market Capitalization
$289.34 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$33.83

Stoke Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
360.9% Upside
$33.83 Price Target
Short Interest
Bearish
19.22% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.59
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.66) to ($2.90) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.14 out of 5 stars

Medical Sector

572nd out of 1,040 stocks

Pharmaceutical Preparations Industry

274th out of 509 stocks

See Top Rated MarketRank™ Stocks Here
STOK stock logo

About Stoke Therapeutics (NASDAQ:STOK) Stock

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

Receive STOK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Stoke Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

STOK Stock News Headlines

November 19, 2022 | americanbankingnews.com
Cantor Fitzgerald Weighs in on Stoke Therapeutics, Inc.'s FY2022 Earnings (NASDAQ:STOK)
November 19, 2022 | americanbankingnews.com
SVB Leerink Comments on Stoke Therapeutics, Inc.'s FY2022 Earnings (NASDAQ:STOK)
November 15, 2022 | marketwatch.com
Stoke Therapeutics Down 26% After Reporting STK-001 Data, 3Q Results
November 15, 2022 | seekingalpha.com
Stoke Therapeutics drops 27% after early data for anti-seizure medicine
November 15, 2022 | finance.yahoo.com
Stoke Therapeutics Stock Falls Post Early Efficacy Data From Lead Dravet Syndrome Program
November 14, 2022 | finance.yahoo.com
Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Tops Revenue Estimates
November 10, 2022 | finance.yahoo.com
Stoke Therapeutics to Host Webinar and Conference Call to Present Interim Data from the Phase 1/2a Studies of STK-001 in Children and Adolescents with Dravet Syndrome
November 10, 2022 | finance.yahoo.com
Is a Surprise Coming for Stoke Therapeutics (STOK) This Earnings Season?
November 7, 2022 | finance.yahoo.com
Stoke Therapeutics, Inc. (STOK) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
October 29, 2022 | forbes.com
Stoke Therapeutics
October 24, 2022 | msn.com
Stoke-on-Trent Tories welcome Sunak's win in race to become next Prime Minister
October 24, 2022 | msn.com
Returning Stoke player should help bring out best in Newcastle Utd old boy says boss
October 24, 2022 | msn.com
Stoke City youngster chasing European spot as impressive loan spell reaches climax
October 24, 2022 | msn.com
Fresh flood warnings in place for Stoke-on-Trent and North Staffordshire
October 23, 2022 | msn.com
Stoke-on-Trent and Staffordshire ambulance workers could be about to go on strike
October 23, 2022 | msn.com
This is the real Stoke City and the big challenge Alex Neil has to get right
October 23, 2022 | msn.com
Stoke City must earn right for home games to be any advantage
October 22, 2022 | msn.com
Stoke City 'too easily beaten' by Coventry City as optimism fades
October 22, 2022 | msn.com
Match report: Liverpool vs Stoke, U18 Premier League
October 22, 2022 | msn.com
Stoke City vs Coventry City LIVE: Championship latest score, goals and updates from fixture
October 22, 2022 | msn.com
'I'll welcome first trainload of asylum seekers to Stoke-on-Trent with balloons and a smile'
October 22, 2022 | msn.com
Bonfire Night crackdown leaves Stoke-on-Trent residents facing £400 fines
October 21, 2022 | msn.com
Stoke City defender 'not going under the radar' with Alex Neil
October 21, 2022 | msn.com
Stoke-on-Trent MP Jonathan Gullis says 'bring back Boris'
October 21, 2022 | msn.com
Stoke City sports bar to open next month after £2.5m renovation
See More Headlines
Receive STOK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Stoke Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

STOK Company Calendar

Last Earnings
11/08/2021
Today
11/28/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/09/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:STOK
CUSIP
N/A
CIK
1623526
Web
www.stoketherapeutics.com
Phone
(781) 430-8200
Fax
N/A
Employees
102
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$33.83
High Stock Price Forecast
$50.00
Low Stock Price Forecast
$20.00
Forecasted Upside/Downside
+360.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($2.61)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-85,810,000.00
Net Margins
N/A
Pretax Margin
-1,093.04%
Return on Equity
-45.07%
Return on Assets
-35.23%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
9.19
Quick Ratio
9.19

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$5.92 per share
Price / Book
1.24

Miscellaneous

Outstanding Shares
39,419,000
Free Float
34,413,000
Market Cap
$289.34 million
Optionable
Not Optionable
Beta
0.70

Key Executives

  • Dr. Edward M. Kaye M.D.Dr. Edward M. Kaye M.D. (Age 73)
    Ph.D., CEO & Director
    Comp: $938.37k
  • Dr. Adrian R. Krainer Ph.D. (Age 63)
    Co-Founder, Independent Director & Member of Scientific Advisory Board
    Comp: $89k
  • Mr. Stephen J. Tulipano CPA (Age 63)
    CPA, MBA, Chief Financial Officer
    Comp: $617.07k
  • Dr. Barry S. Ticho FACC (Age 61)
    M.D., Ph.D., Chief Medical Officer
    Comp: $664.99k
  • Ms. Isabel Aznarez Ph.D. (Age 49)
    Co-Founder & Group VP of Discovery Research
  • Dr. Huw M. Nash Ph.D. (Age 55)
    COO & Chief Bus. Officer
  • Mr. Jonathan Allan J.D.
    Gen. Counsel
  • Ms. Dawn Kalmar (Age 44)
    Chief Communications Officer
  • Ms. Joan Wood
    Chief HR Officer
  • Ms. Shamim Ruff (Age 62)
    Chief Regulatory Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













STOK Stock - Frequently Asked Questions

Should I buy or sell Stoke Therapeutics stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Stoke Therapeutics in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" STOK shares.
View STOK analyst ratings or view top-rated stocks.

What is Stoke Therapeutics' stock price forecast for 2023?

6 Wall Street analysts have issued 12-month price targets for Stoke Therapeutics' stock. Their STOK share price forecasts range from $20.00 to $50.00. On average, they predict the company's stock price to reach $33.83 in the next twelve months. This suggests a possible upside of 360.9% from the stock's current price.
View analysts price targets for STOK or view top-rated stocks among Wall Street analysts.

How have STOK shares performed in 2022?

Stoke Therapeutics' stock was trading at $23.99 on January 1st, 2022. Since then, STOK shares have decreased by 69.4% and is now trading at $7.34.
View the best growth stocks for 2022 here.

When is Stoke Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 9th 2023.
View our STOK earnings forecast.

How were Stoke Therapeutics' earnings last quarter?

Stoke Therapeutics, Inc. (NASDAQ:STOK) issued its earnings results on Monday, November, 8th. The company reported ($0.61) earnings per share for the quarter, missing the consensus estimate of ($0.57) by $0.04.

What other stocks do shareholders of Stoke Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Stoke Therapeutics investors own include Gossamer Bio (GOSS), Editas Medicine (EDIT), Alector (ALEC), LogicBio Therapeutics (LOGC), NVIDIA (NVDA), Precision BioSciences (DTIL), Kaleido Biosciences (KLDO), Homology Medicines (FIXX), Marvell Technology (MRVL) and Invitae (NVTA).

When did Stoke Therapeutics IPO?

(STOK) raised $100 million in an IPO on Wednesday, June 19th 2019. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Credit Suisse served as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is Stoke Therapeutics' stock symbol?

Stoke Therapeutics trades on the NASDAQ under the ticker symbol "STOK."

Who are Stoke Therapeutics' major shareholders?

Stoke Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (5.20%), BlackRock Inc. (4.33%), Healthcare of Ontario Pension Plan Trust Fund (2.28%), Bank of Montreal Can (1.95%), Price T Rowe Associates Inc. MD (1.05%) and State Street Corp (1.04%). Insiders that own company stock include Apple Tree Partners Iv, LP, Arthur Tzianabos, Barry Ticho, Edward M Md Kaye, Gene Liau, Huw M Nash, Huw M Nash, Robin A Walker and Stephen J Tulipano.
View institutional ownership trends.

How do I buy shares of Stoke Therapeutics?

Shares of STOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Stoke Therapeutics' stock price today?

One share of STOK stock can currently be purchased for approximately $7.34.

How much money does Stoke Therapeutics make?

Stoke Therapeutics (NASDAQ:STOK) has a market capitalization of $289.34 million. The company earns $-85,810,000.00 in net income (profit) each year or ($2.61) on an earnings per share basis.

How many employees does Stoke Therapeutics have?

The company employs 102 workers across the globe.

How can I contact Stoke Therapeutics?

Stoke Therapeutics' mailing address is 45 WIGGINS AVENUE, BEDFORD MA, 01730. The official website for the company is www.stoketherapeutics.com. The company can be reached via phone at (781) 430-8200 or via email at ir@stoketherapeutics.com.

This page (NASDAQ:STOK) was last updated on 11/28/2022 by MarketBeat.com Staff